In this section:

02 July 2019

Dovobet Gel recalled at pharmacy level

No need for a new prescription if you have an affected product, but speak to your doctor if concerned.

TMHRA logohe Medicines and Healthcare products Regulatory Agency (MHRA) has announced a precautionary pharmacy level recall for some prescription medications including Dovobet Gel, which is used for the treatment of psoriasis. This means that products from affected stocks will be recalled from pharmacies.

The reason for the recall is due to the products being taken out of the regulated medicines’ supply chain during distribution, and later reintroduced.

This means that storage conditions whilst in transit cannot be guaranteed, with the MHRA stating that ‘while unlikely, this could impact their effectiveness’. They also said that the medicines do not appear to have been tampered with, and are at a stable room temperature, ‘this means that the risk of these medicines not being fully effective is greatly reduced or negligible.’

Patients are being advised to continue using Dovobet Gel, and not to arrange a new prescription, however if you are worried or have any questions you should contact your GP or healthcare professional.

The press release can be found here, and a full list of the affected batches can be found here.

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you. If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them. Close